Nymox Pharmaceutical reported total assets of $0.58M and total liabilities of $9.88M for the quarter ended Dec 2025, down 13.9% year over year. This balance sheet covers 33 quarters of results from Dec 2015 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Dec2015 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Sep2024 | Dec2024 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||||||||||
| Current Assets | |||||||||||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 5.24M | 3.00M | 0.77M | 5.37M | 3.61M | 3.14M | 0.83M | 0.67M | 4.07M | 2.70M | 1.40M | 0.35M | 0.13M | 0.08M | 0.07M | 0.04M | 0.07M | 0.01M | |||||||||||||||
| Cash & Current Investments | 5.24M | 3.00M | 0.77M | 5.37M | 3.61M | 3.14M | 0.83M | 0.67M | 4.07M | 2.70M | 1.40M | 0.35M | 0.13M | 0.08M | 0.07M | 0.04M | 0.07M | 0.01M | |||||||||||||||
| Receivables - NetNet Receivables | 0.00M | 0.00M | 0.00M | 0.00M | |||||||||||||||||||||||||||||
| Receivables - OtherOther Receivables | 0.01M | 0.01M | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.02M | 0.03M | ||||||||||||||
| Receivables | 0.02M | 0.01M | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | 0.03M | ||||||||||||||||||||||||
| Inventory | 0.02M | 0.02M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | |||||||||||||||||||||
| Prepaid Assets | 0.10M | 0.01M | |||||||||||||||||||||||||||||||
| Current Assets | 5.33M | 3.13M | 0.89M | 5.63M | 3.89M | 1.06M | 6.34M | 3.39M | 1.04M | 0.89M | 4.19M | 2.91M | 1.46M | 0.46M | 0.21M | 0.65M | 0.63M | 0.62M | 0.65M | 0.58M | |||||||||||||
| Non-Current Assets | |||||||||||||||||||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.03M | 0.02M | 0.02M | 0.02M | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M | |||||||||||||
| Goodwill & Intangibles | 2.22M | 2.22M | 2.22M | 2.22M | 4.45M | 4.45M | 4.45M | ||||||||||||||||||||||||||
| Long-Term Deferred Tax | 1.40M | ||||||||||||||||||||||||||||||||
| Other Non-Current Assets | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.04M | 0.04M | |||||||||||||||||||
| Non-Current Assets | 0.16M | 0.24M | 0.17M | 0.11M | 0.45M | 0.39M | 0.34M | 0.46M | 0.41M | 0.35M | 0.29M | 0.23M | 0.17M | 0.11M | 0.06M | 0.02M | 0.00M | 0.00M | 0.00M | 0.00M | |||||||||||||
| Assets | 5.49M | 3.37M | 1.06M | 5.74M | 4.34M | 1.46M | 6.67M | 3.85M | 1.44M | 1.24M | 4.47M | 3.14M | 1.63M | 0.58M | 0.27M | 0.67M | 0.63M | 0.62M | 0.65M | 0.58M | |||||||||||||
| Liabilities | |||||||||||||||||||||||||||||||||
| Current Liabilities | |||||||||||||||||||||||||||||||||
| Accounts Payables | 1.89M | 1.71M | 1.96M | 1.80M | 1.77M | 1.10M | 1.65M | 1.82M | 1.56M | 1.93M | 3.90M | 4.05M | |||||||||||||||||||||
| Payables | 1.89M | 1.71M | 1.96M | 1.80M | 1.77M | 1.10M | 1.65M | 1.82M | 1.56M | 1.93M | 3.90M | 4.05M | |||||||||||||||||||||
| Accumulated Expenses | 0.04M | 0.07M | 0.02M | 1.96M | 2.14M | 1.93M | 2.26M | 2.34M | 2.56M | 3.05M | 4.31M | 3.90M | 4.05M | ||||||||||||||||||||
| Other Accumulated Expenses | 0.66M | ||||||||||||||||||||||||||||||||
| Short term Debt | 0.00M | 0.37M | 0.34M | 0.31M | 0.45M | ||||||||||||||||||||||||||||
| Total Current Liabilities | 2.04M | 1.81M | 2.02M | 1.90M | 1.97M | 1.13M | 1.66M | 1.82M | 1.79M | 2.52M | 2.19M | 2.36M | 2.11M | 2.37M | 3.15M | 2.57M | 3.80M | 6.92M | 7.43M | 9.88M | |||||||||||||
| Non-Current Liabilities | |||||||||||||||||||||||||||||||||
| Operating Leases | 0.00M | 0.23M | 0.16M | 0.11M | 0.23M | 0.22M | 0.17M | 0.11M | 0.06M | 0.01M | |||||||||||||||||||||||
| Total Liabilities | 2.04M | 1.93M | 2.12M | -32.70M | 2.20M | 1.47M | 1.96M | 2.27M | 1.95M | 2.63M | 2.24M | 2.37M | 2.11M | 2.37M | 3.15M | 2.57M | 3.80M | 6.92M | 7.43M | 9.88M | |||||||||||||
| Shareholder's Equity | |||||||||||||||||||||||||||||||||
| Total Debt | 0.00M | 0.37M | 0.34M | 0.31M | 0.45M | ||||||||||||||||||||||||||||
| Common Equity | 3.45M | 1.44M | -1.06M | 38.44M | 2.15M | -0.01M | 4.71M | 1.58M | -0.51M | -1.39M | 2.23M | 0.77M | -0.48M | -1.80M | -2.88M | -1.90M | -3.17M | -6.30M | -6.78M | -9.31M | |||||||||||||
| Liabilities and Shareholders Equity | 5.49M | 3.37M | 1.06M | 5.74M | 4.34M | 1.46M | 6.67M | 3.85M | 1.44M | 1.24M | 4.47M | 3.14M | 1.63M | 0.58M | 0.27M | 0.67M | 0.63M | 0.62M | 0.65M | 0.58M | |||||||||||||
| Retained Earnings | -168.29M | -170.90M | -173.84M | -178.00M | -180.03M | -182.46M | -186.45M | -189.75M | -192.56M | -197.65M | -199.14M | -207.98M | -212.47M | -216.75M |
Pull Nymox Pharmaceutical's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NYMXF&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NYMXF", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NYMXF&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();